EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma

Lynnette Wei Hsien Koh, Qing You Pang, Wisna Novera, See Wee Lim, Yuk Kien Chong, Jinyue Liu, Samantha Ya Lyn Ang, Ron Weng Yee Loh, Huilin Shao, Jianhong Ching, Yulan Wang, Stephen Yip iD und 8 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noae206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Lynnette Wei Hsien Koh und 19 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Research Laboratory, Department of Research, National Neuroscience Institute, Singapore, Singapore. Hauptthemen laut MEDLINE: Enhancer of Zeste Homolog 2 Protein, Glioblastoma, Reactive Oxygen Species, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Singapore Ministry of Health's National Medical Research Council, National Research Foundation Singapore, Singapore Ministry of Health’s National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Enhancer of zeste homolog 2 (EZH2), well known for its canonical methyltransferase activity in transcriptional repression in many cancers including glioblastoma (GBM), has an understudied noncanonical function critical for sustained tumor growth. Recent GBM consortial efforts reveal complex molecular heterogeneity for which therapeutic vulnerabilities correlated with subtype stratification remain relatively unexplored. Current enzymatic EZH2 inhibitors (EZH2inh) targeting its canonical su(var)3–9, enhancer-of-zeste and trithorax domain show limited efficacy and lack durable response, suggesting that underlying differences in the noncanonical pathway may yield new knowledge. Here, we unveiled dual roles of the EZH2 CXC domain in therapeutically distinct, reactive oxygen species (ROS)-stratified tumors.

Methods

We analyzed differentially expressed genes between ROS classes by examining cis-regulatory elements as well as clustering of activities and pathways to identify EZH2 as the key mediator in ROS-stratified cohorts. Pull-down assays and CRISPR knockout of EZH2 domains were used to dissect the distinct functions of EZH2 in ROS-stratified GBM cells. The efficacy of NF-κB-inducing kinase inhibitor (NIKinh) and standard-of-care temozolomide was evaluated using orthotopic patient-derived GBM xenografts.

Results

In ROS(+) tumors, CXC-mediated co-interaction with RelB drives constitutive activation of noncanonical NF-κB2 signaling, sustaining the ROS(+) chemoresistant phenotype. In contrast, in ROS(−) subtypes, Polycomb Repressive Complex 2 methyltransferase activity represses canonical NF-κB. Addressing the lack of EZH2inh targeting its nonmethyltransferase roles, we utilized a brain-penetrant NIKinh that disrupts EZH2-RelB binding, consequently prolonging survival in orthotopic ROS(+)-implanted mice.

Conclusions

Our findings highlight the functional dichotomy of the EZH2 CXC domain in governing ROS-stratified therapeutic resistance, thereby advocating for the development of therapeutic approaches targeting its noncanonical activities and underscoring the significance of patient stratification methodologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Enhancer of Zeste Homolog 2 ProteinGlioblastomaReactive Oxygen SpeciesBrain NeoplasmsHumansAnimalsMiceXenograft Model Antitumor AssaysTumor Cells, CulturedGene Expression Regulation, NeoplasticCell Proliferation

Stichwörter der Autor:innen

EZH2brain cancerglioblastomapatient stratificationprecision medicine

Substanzen

Enhancer of Zeste Homolog 2 ProteinReactive Oxygen SpeciesEZH2 protein, human

Autor:innen und Institutionen

  • Neuro-Oncology Research Laboratory, Department of Research, National Neuroscience Institute, Singapore, Singapore.
  • Laboratory of Single-Cell Spatial Neuromics, Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
  • Department of Neurosurgery, National Neuroscience Institute, Singapore, Singapore.
  • SingHealth Duke-NUS Neuroscience Academic Clinical Programme, Duke-National University of Singapore Medical School, Singapore, Singapore.
  • Enabling Village, SG Enable, Singapore, Singapore.
  • Institute for Health Innovation & Technology, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Stephen Yip, Nguan Soon Tan, Carol Tang

Förderung

  • Singapore Ministry of Health's National Medical Research Council
  • National Research Foundation Singapore
  • Singapore Ministry of Health’s National Medical Research Council

Zitieren

APA

Koh, L. W. H., Pang, Q. Y., Novera, W., Lim, S. W., Chong, Y. K., Liu, J., Ang, S. Y. L., Loh, R. W. Y., Shao, H., Ching, J., Wang, Y., Yip, S., Tan, P., Li, S., Low, D. C. Y., Phelan, A., Rosser, G., Tan, N. S., Tang, C., & Ang, B. T. (2025). EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae206

Vancouver

Koh LWH, Pang QY, Novera W, Lim SW, Chong YK, Liu J, et al. EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma. Neuro-Oncology. 2025. doi:10.1093/neuonc/noae206

BibTeX
@article{Koh2025,
  author = {Koh, Lynnette Wei Hsien and Pang, Qing You and Novera, Wisna and Lim, See Wee and Chong, Yuk Kien and Liu, Jinyue and Ang, Samantha Ya Lyn and Loh, Ron Weng Yee and Shao, Huilin and Ching, Jianhong and Wang, Yulan and Yip, Stephen and Tan, Patrick and Li, Shang and Low, David Chyi Yeu and Phelan, Anne and Rosser, Gabriel and Tan, Nguan Soon and Tang, Carol and Ang, Beng Ti},
  title = {EZH2 functional dichotomy in reactive oxygen species-stratified glioblastoma},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noae206}
}
Kostenlos starten →